Patient Search
 |
 |
|
KaCrole Higgins was diagnosed with breast cancer in 2020. “In May 2020, I found a lump in my breast. I cried. By June, it was diagnosed as breast cancer, triple positive, stage 1A. While getting this cancer diagnosis was devastating, it also became an opportunity. Suddenly, the cancer gave me clarity. It gave me clarity about what was important, what was good in my life, what was toxic in my life, and what I needed to do.” Click below to read more of KaCrole’s story |
If Landon Ryan had been diagnosed with bilateral retinoblastoma 10, 20 or 30 years ago, she might not be here today with nearly perfect vision.Thanks to recent improvements in the treatment for this rare form of cancer that almost exclusively affects children under the age of 5, the diagnosis had the power to change Landon’s life when she was 11 months old, but not to take it — or her eyesight. Click below to learn more about Landon and her story. https://momentum.vicc.org/2022/04/brighter-outlook/ |
A Phase 1/2 Study of M3814 (Peposertib) in Combination With Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma
Pancreatic
Pancreatic
Pancreatic
I/II
Cardin, Dana
NCT04172532
NCIGIP10366
Phase 2 Study of Ruxolitinib-Based Primary Treatment for Acute GVHD
Multiple Cancer Types
Leukemia,
Lymphoma,
Multiple Myeloma,
Myelodysplastic Syndrome
II
Kitko, Carrie
NCT06936566
VICCCTT25042
Randomized Phase III Trial of Neoadjuvant Immunotherapy with Response-Adapted Treatment versus Standard-of-Care Treatment for Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma
Head/Neck
Head/Neck
Head/Neck
III
Choe, Jennifer
NCT06568172
NRGHNHN014
Disposable Perfusion Phantom for Accurate DCE-MRI Measurement of Pancreatic Cancer Therapy Response
Pancreatic
Pancreatic
Pancreatic
N/A
Xu, Junzhong
NCT04588025
VICCGI2099
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)
Not Available
III
Not Available
NCT03126916
COGANBL1531
A Phase 2 Study of Blinatumomab (NSC# 765986, IND# 125462) in Combination with Nivolumab (NSC# 748726, IND# 125462), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/=1 to <31 Years Old with First Relapse
Not Available
II
Not Available
NCT04546399
COGAALL1821
Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-BCMA-ALLO1 in Subjects with Relapsed/Refractory Multiple Myeloma (MM)
Multiple Cancer Types
Multiple Myeloma,
Phase I
I
Dholaria, Bhagirathbhai
NCT04960579
VICCCTTP2232
A Randomized Phase 2 Non-inferiority Trial of (Z)-endoxifen and Exemestane + Goserelin as Neoadjuvant Treatment for Premenopausal Women with ER+/HER2- Breast Cancer.
Breast
Breast
Breast
II
Abramson, Vandana
NCT05607004
VICCBRE22108
A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination with Cemiplimab in Patients with Advanced Solid Tumors
Multiple Cancer Types
Adrenocortical,
Bladder,
Breast,
Cervical,
Colon,
Esophageal,
GIST,
Gastric/Gastroesophageal,
Gastrointestinal,
Gynecologic,
Head/Neck,
Kidney (Renal Cell),
Liver,
Lung,
Miscellaneous,
Non Small Cell,
Ovarian,
Pancreatic,
Phase I,
Prostate,
Rectal,
Urologic,
Uterine
I/II
Choe, Jennifer
NCT04626635
VICC-DTPHI24031
Consolidative Use of Radiotherapy to Block (CURB2) Oligoprogression in Patients with Metastatic Non-Small-Cell Lung Cancer - A Randomized Phase 3 Trial
Lung
Lung
Lung
III
Osmundson, Evan
NCT06686771
NRGTHOCCTGBR38
